Table 2. Characteristics of Kidney Transplant Recipients.
| Recipient characteristics | Kidney transplant recipientsa | Standardized mean difference | |
|---|---|---|---|
| Matched donor underwent dialysis (n = 954) | Matched donor did not undergo dialysis (n = 990) | ||
| Cold ischemic time, median (IQR), h | 19 (13.7 to 25) | 15 (9.8 to 21.4) | 0.41 |
| Age, mean (SD), y | 52.7 (13.8) | 49.2 (15.2) | 0.24 |
| Sex | |||
| Male | 580 (60.8) | 605 (61.1) | −0.0064 |
| Female | 374 (39.2) | 385 (38.9) | 0.0064 |
| Self-identified race | |||
| Black | 279 (29.2) | 299 (30.2) | −0.021 |
| Otherb | 675 (70.8) | 691 (69.8) | 0.021 |
| Body mass index, mean (SD)c | 28 (5.4) | 28 (5.7) | −0.0045 |
| End-stage kidney disease caused by diabetes | 273 (28.6) | 294 (29.7) | −0.024 |
| Level of human leukocyte antigen mismatch, mean (SD) | 4.3 (1.4) | 4.1 (1.5) | 0.12 |
| Undergoing dialysis prior to transplant, median (IQR), y | 4.1 (2.3 to 6.6) | 3.8 (1.8 to 6.2) | 0.11 |
| Preemptive transplantd | 97 (10.2) | 131 (13.2) | −0.095 |
| Previous transplant | 77 (8.1) | 114 (11.5) | −0.12 |
| Panel reactive antibody category, % | |||
| 0 | 640 (67.1) | 591 (59.7) | 0.15 |
| 1-20 | 63 (6.6) | 93 (9.4) | −0.1 |
| 21-80 | 144 (15.1) | 140 (14.1) | −0.027 |
| >80 | 107 (11.2) | 166 (16.8) | −0.016 |
| Induction immunosuppression therapye | |||
| Corticosteroid | 687 (72) | 642 (64.8) | 0.15 |
| Antithymocyte globulin | 593 (62.2) | 564 (57) | 0.11 |
| Basiliximab | 181 (19) | 198 (20) | −0.026 |
| Alemtuzumab | 147 (15.4) | 132 (13.3) | 0.059 |
| Other therapyf | 23 (2.4) | 35 (3.5) | −0.066 |
| Maintenance immunosuppression therapy at discharge from index hospitalization for transplante | |||
| Mycophenolate | 915 (95.9) | 946 (95.6) | 0.018 |
| Tacrolimus | 901 (94.4) | 935 (94.4) | 0 |
| Corticosteroid | 681 (71.4) | 696 (70.3) | 0.024 |
| Cyclosporine | 19 (2) | 21 (2.1) | −0.0091 |
| Belatacept | 19 (2) | 17 (1.7) | 0.02 |
| Other therapyg | 15 (1.6) | 24 (2.4) | −0.061 |
a
Data are expressed as No. (%) unless otherwise indicated.
b
Includes American Indian, Asian, Pacific Islander, White, and multiple races.
c
Calculated as weight in kilograms divided by height in meters squared.
d
Defined as receipt of a kidney transplant before requiring chronic kidney replacement therapy.
e
The sum of percentages exceeds 100% because patients may have required the use of multiple immunosuppressive agents.
f
Included belatacept, antithymocyte globulin, muromonab, rituximab, sirolimus, intravenous immunoglobulin, or bortezomib.
g
Included azathioprine, everolimus, sirolimus, rituximab, or intravenous immunoglobulin.